APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Clinical trial NCT03745716 · COMPLETED
Trial details
- NCT number
- NCT03745716
- Sponsor
- Aprea Therapeutics
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-11
- Primary completion
- 2020-11-27
- Enrollment
- 154
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.